27 April 2022PatentsMaryAnne Armstrong

Label ruling upends generic medicine makers

In August 2021, the Court of Appeal for the Federal Circuit (CAFC), in a per curiam opinion, quietly decided one of the most important pharma cases in recent years in GlaxoSmithKline v Teva Pharmaceuticals USA (Fed Cir 2021).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Patents

Federal Circuit overturns L’Oreal’s $66m haircare patent loss

7 May 2021 L’Oreal has convinced the Federal Circuit to partially reverse a district court ruling ordering it to pay $66 million for infringing two patents and stealing trade secrets from cosmetics startup Olaplex.

Patents

Federal Circuit decries ‘untimely’ LG patent verdict challenge

4 August 2021 LG Electronics will have to wait to appeal a judgment that it infringed a video display patent, the US Court of Appeals for the Federal Circuit ruled yesterday.

On our radar...

Philip Morris case triggers AIPPI call for EPO action

Penn State prevails in trademark dispute with Vintage Brand over retro logos

Google: Ex-engineer ‘touted dominion over the trade secrets he stole’

OpenAI faces first copyright suit in India over alleged scraping of news content

Tourism’s influence on defining the ‘relevant public’ in EUTM oppositions

‘Trade secrets can be emotional’: Seth Gerber, Morgan Lewis

Private equity eyes controlling interest in Anaqua

Label ruling upends generic medicine makers

More on this story

Editor's picks

Editor's picks

More articles